Tumor progression is also often associated with systemic lymphocyte perturbations, characterized by increased regulatory T cell (Treg) frequencies33–35, and reduced CD8+ and conventional CD4+ T cells in the blood of cancer patients36,37. This evidence concerns the gene CD8A and cancer.